New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
12:07 EDTZMHZimmer unlikely to be strongly impacted by AAOS guidance, says Wells Fargo
Wells Fargo reports that the American Academy of Orthopedic Surgeons, or AAOS, will recommend against the use of hyaluronic acid, or HA, for osteoarthritis of the knee, while Zimmer is in the process of launching its single injection HA, Gel-one in the U.S. The firm thinks the guidance could have a temporary negative impact on HA, but it doesn't expect the impact on Zimmer to be dramatic. The firm doesn't expect doctors who have already had success with HA to stop using it, and it maintains an Outperform rating on Zimmer.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
08:15 EDTZMHZimmer should be bought on any weakness from Q2 results, says RBC Capital
RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.
July 10, 2014
09:06 EDTZMHBofA/Merrill remains bullish on Zimmer
BofA/Merrill said BMET reported solid Q4 results, which bode well for Zimmer (ZMH). The firm rates ZImmer a Buy with a $125 price target and a best idea.
06:42 EDTZMHBiomet reports Q4 net sales up 7.7% to $844.5M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use